Last updated on July 2011

Single Agent Abraxane as Second Line Therapy in Bladder Cancer


Brief description of study

The purpose of this study is to determine what effects the drug Abraxane has on bladder cancer.

Detailed Study Description

For those patients with advanced bladder cancer who have progressed on a platinum based regimen, no widely accepted standard second line therapy currently exists. Taxanes including paclitaxel have exhibited clinical activity in this disease and are sometimes given off study. However, toxicities including neurotoxicity and hypersensitivity reactions often limit the use of paclitaxel. ABRAXANE may allow delivery of a greater dose of paclitaxel to those with bladder cancer with an easier method of administration and with less toxicity.

Clinical Study Identifier: NCT00683059

Contact Investigators or Research Sites near you

Start Over

Som Mukherjee, MD

Juravinski Cancer Centre
Hamilton, ON Canada
  Connect »

Eric Winquist, MD

London Regional Cancer Program
London, ON Canada
  Connect »

Christina Canil, MD

Ottawa Regional Cancer Centre
Ottawa, ON Canada
  Connect »

Srikala Sridhar, MD

Princess Margaret Hospital
Toronto, ON Canada
  Connect »

Yoo-Joung Ko, MD

Sunnybrook Health Sciences Centre
Toronto, ON Canada
  Connect »